Yüklüyor......

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms

Considerable clinical experience regarding the long-term efficacy and safety of ruxolitinib has been gathered since the drug was approved in the USA for patients with intermediate or high-risk myelofibrosis (MF) in November 2011. Findings from the pivotal phase 3 COMFORT studies showed that ruxoliti...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Curr Hematol Malig Rep
Asıl Yazarlar: Yacoub, A., Odenike, O., Verstovsek, S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2014
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4223534/
https://ncbi.nlm.nih.gov/pubmed/25145552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11899-014-0229-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!